(Reuters) – The European drug regulator on Thursday gave the green light to Pfizer’s Covid-19 antiviral pill to treat adults at risk of developing severe illness as the region struggles to boost its arsenal to fight the disease. Omicron variant of the coronavirus.
The European Medicines Agency (EMA) endorsement for conditional approval, if followed as usual by the European Commission, allows EU member states to use the drug after the body offered emergency use guidance late last year.
+ Anvisa cancels authorization granted to Israeli antiviral spray
Italy, Germany and Belgium are among the EU countries that bought the drug, called Paxlovid.
In December, the United States authorized Paxlovid and a similar drug, MSD’s molnupravir.
MSD’s pill is also being reviewed in the EU but is taking longer to get approved as the company reviewed study data in November saying the drug was significantly less effective than previously thought.
(Reporting by Mrinalika Roy and Manas Mishra in Bengaluru, Ludwig Burger in Frankfurt; additional reporting by Francesco Guarascio)
know more
+ SP: Man dies standing, leaning against car, and scene scares residents on the coast
+ One twin became vegan, the other ate meat. Check the result
+ Reincarnation in history: an age-old belief
+ Andressa Urach asks for money on the internet: ‘Help me pay my card bill’
+ Horoscope: check today’s forecast for your sign
+ CNH: see what you need to know for the application and renewal
+ See which were the most stolen cars in SP in 2021
+ Expedition identifies giant squid responsible for ship sinking in 2011
+ Everything you need to know before buying a crockpot
+ US Agency warns: never wash raw chicken meat
+ What is known about fluorone?
+ Trick to squeeze lemons becomes a craze on social media
+ IPVA 2022 SP: see how to consult and pay the tax
#European #regulator #approves #Pfizer #antiviral #treat #Covid